Login/Register

Advanced Oncotherapy adds Jonathan Farr as senior VP

Company News

Advanced Oncotherapy adds Jonathan Farr as senior VP

Wed, 14 June 2017
Article viewed 61 times
http://stmedia.digitallook.com/web/img/dl/laboratorysecondfloor_opt.jpg
bool(true)
Advanced Oncotherapy adds Jonathan Farr as senior VP

(ShareCast News) - Next-generation proton therapy systems developer Advanced Oncotherapy announced the appointment of Jonathan Farr as senior vice-president of medical physics with immediate effect on Wednesday.
The AIM-traded firm said Dr Farr would not be taking a board position.

It said Dr Farr is a medical physicist working in the treatment of cancer, specialising in proton therapy.

His experience in developing "high definition and accurate" proton treatment systems, their clinical use and characterisation, advanced radiotherapy treatment planning and novel image guidance and patient positioning, closely matched the company's goal of commercialising the next generation of proton therapy systems, the board claimed.

He would be based in Geneva, and would be leading the clinical application of and further advances in LIGHT's patient treatment systems.

"Jonathan provides us with extensive expertise in proton therapy patient treatment," said CEO Nicolas Serandour.

"He has a keen interest in innovation and is ideally suited to maximise the clinical benefits from LIGHT's next-generation technology.

"His appointment, alongside Ed Lee's, which was announced on 13 June, is a further endorsement of the ground-breaking work we are doing at Advanced Oncotherapy."

Commenting on his appointment, Dr Farr said the "next generation" of proton therapy, embodied in AVO's technologically system, would make proton therapy more effective and accessible.

"My new role with AVO is translating the complex proton therapy system into powerful and efficient application at the clinical level.

"Together with my experienced colleagues, we are working on optimisations to leverage the LIGHT system from clinical, patient access and shareholder points of view," Dr Farr said.

"My international experience, honed in Europe and the United States, provides me with the unique ability to do this."